Lecanemab and donanemab were hailed as 'the beginning of the end' of dementia last year, after studies showed they both ...

NICE’s interim second draft guidance does not recommend lecanemab for use within the NHS in England and Wales at this time.

The rapid influx of new medications brought to market over the past decade has revolutionized health care by offering new ...

A special edition of the journal Science focuses on women's health, including links between estrogen and dementia, at a time ...

Systematic fraud -- led by a "cabal of self-interested researchers, government accomplices, and corporate greed" in the words ...

Leqembi’s application now moves forward to the European Commission, which will issue a formal verdict for the injection that ...

Eisai (ESAIY) and Biogen (BIIB) announced that the Therapeutic Goods Administration, TGA, of Australia has confirmed the initial decision to ...

St. Charles, Missouri, resident Sue Bell became one of the first Alzheimer's patients in the U.S. to receive the drug now ...

The European Union’s medicines regulator on Friday reiterated its positive recommendation for Eisai and Biogen’s Alzheimer’s ...

Eli Lilly and Co. to discover, develop and commercialize molecular glue therapeutics for oncology. “It’s a really important deal, especially given the discovery of Trueglues is something Magnet is ...

The European Commission had requested the committee consider new data on the drug that became available after it had adopted its positive opinion.